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AbstrAct
Introduction Persisting neurotropic viruses are 
proposed to increase the risk of dementia, but 
evidence of association from robust, adequately 
powered population studies is lacking. This is 
essential to inform clinical trials of targeted preventive 
interventions.
Methods and analysis We will carry out a 
comprehensive systematic review of published and 
grey literature of the association between infection 
with, reactivation of, vaccination against or treatment 
of any of the eight human herpesviruses and dementia 
or mild cognitive impairment. We will search the 
Cochrane Library, Embase, Global Health, Medline, 
PsycINFO, Scopus, Web of Science, clinical trials 
registers, the New York Academy of Medicine Grey 
Literature Report, Electronic Theses Online Service 
through the British Library and the ISI Conference 
Proceedings Citation Index for randomised controlled 
trials, cohort, case–control, case crossover or self-
controlled case series studies reported in any language 
up to January 2017. Titles, abstracts and full-text 
screening will be conducted by two researchers 
independently. Data will be extracted systematically 
from eligible studies using a piloted template. We 
will assess risk of bias of individual studies in line 
with the Cochrane Collaboration tool. We will conduct 
a narrative synthesis, grouping studies by exposure 
and outcome definitions, and will describe any 
differences by population subgroups and dementia 
subtypes. We will consider performing meta-analyses 
if there are adequate numbers of sufficiently 
homogeneous studies. The overall quality of cumulative 
evidence will be assessed using selected Grading of 
Recommendations, Assessment, Development and 
Evaluations criteria.
Ethics and dissemination As this is a review of 
existing studies, no ethical approval is required. 
Results will be disseminated through a peer-
reviewed publication and at national and international 
conferences. We anticipate the review will clarify 
the current extent and quality of evidence for a link 
between herpesviruses and dementia, identify gaps 
and inform the direction of future research.
Prospero registration number CRD42017054684.
IntroductIon
rationale
Dementia has now overtaken ischaemic 
heart disease as the leading cause of death 
in England and Wales.1 The prevalence is 
forecast to rise rapidly as the population 
ages, with the number of dementia cases 
worldwide projected to reach 131.5 million 
in 2050 compared with 46.8 million in 2015,2 
assuming that age-specific prevalence rates 
remain stable.3 After accounting for overlap 
between risk factors, only around one-third 
of dementia cases are attributable to poten-
tially preventable factors,4 and there are no 
effective treatments. It is therefore essential 
to identify other modifiable determinants.
Viral aetiologies for dementia have been 
postulated for decades, but population-level 
evidence is inconsistent and no antiviral strat-
egies to reduce dementia risk are in routine 
clinical use. Recent interest has focused on 
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Protocol
Strengths and limitations of this study
 ► This systematic review will comprehensively 
evaluate published and grey literature on the 
association between infection with, reactivation 
of, vaccination against or treatment of any of the 
eight human herpesviruses and dementia or mild 
cognitive impairment.
 ► One key strength of our review is that it will 
assess the evidence for differential effects of 
human herpesviruses on dementia risk in different 
population subgroups, for example, by age, 
ethnicity and immune status, to inform the design 
and targeting of randomised controlled trials of 
preventive interventions to reduce dementia risk.
 ► A lack of adequately powered studies or heterogeneity 
of studies selected for inclusion in terms of study 
design, exposure and outcome definitions or study 
population may restrict our capacity to derive clear 
conclusions about the study question.
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herpes simplex virus type 1 (HSV1),5 6 one of eight human 
herpesviruses that routinely infect humans. After primary 
infection, all human herpesviruses establish latency within 
specific tissues, with the alpha herpesviruses HSV1, HSV2 
and varicella zoster virus (VZV) demonstrating neurotro-
pism through their characteristic persistence in sensory 
nerve ganglia.7
HSV1 infection of neuronal and glial cell cultures 
induces cellular changes similar to those seen in Alzhei-
mer’s disease (AD),8–10 and which are reversible using 
antiviral agents.11 Postmortem studies show that HSV 
establishes latency in human brain tissue: viral genomic 
sequences have been detected in up to 35% of neuro-
logically asymptomatic individuals12; HSV reactivation 
from latency occurs in explanted mouse brainstems.13 14 
A meta-analysis of mainly small case–control studies of 
varying quality published in 2015 suggested that HSV1 
seropositivity was associated with an increased risk of AD 
(pooled OR 1.38 (95% CI 1.03 to 1.84)) as was the pres-
ence of Epstein-Barr virus (EBV) antibodies (pooled OR 
1.55 (95% CI 1.12 to 2.13)).15 Although the presence of 
any of six herpesviruses in brain tissue was associated with 
AD in case–control studies (pooled OR 1.38 (95% CI 1.14 
to 1.66)), the temporal sequence and clinical significance 
of this finding are unclear.
Our study will have some key differences to this 
previous review: we will consider the effect of infection 
with and reactivation of all eight human herpesviruses on 
both AD and other neurodegenerative diseases causing 
dementia or mild cognitive impairment (MCI); we will 
investigate whether preventing or treating herpesvirus 
infections affects dementia risk; and we will assess the 
evidence for differential effects of human herpesviruses 
on dementia risk in different population subgroups, for 
example, by age, ethnicity, socioeconomic status and 
immune status, to inform the design and targeting of 
randomised controlled trials (RCTs) of preventive inter-
ventions.
objectives
The overall aim is to determine whether people infected 
with any of the eight human herpesviruses are at greater 
risk of subsequently developing dementia or MCI than 
those without evidence of herpesvirus infection.
Specific research questions include the following:
1. Does primary infection with or reactivation of human 
herpesviruses affect the risk of dementia or MCI?
2. Does preventing or treating human herpesviruses 
modulate dementia or MCI risk?
3. Does any association between human herpesviruses 
and dementia or MCI vary by population subgroups 
or between subtypes of dementia?
Methods
This systematic review protocol has been prepared 
according to the Preferred Reporting Items for System-
atic Review and Meta-Analysis Protocols 2015 statement.16
eligibility criteria
Study design
We will include all RCTs, prospective and retrospective 
cohort studies, case–control studies, self-controlled case 
series and case crossover studies that either present an 
estimate of effect or provide sufficient data for an effect 
estimate to be calculated.
Population
Our study population will include adults aged 18 years and 
over, with results stratified where possible by age group, 
immune status and apolipoprotein E4 (APOE4) status. 
Studies conducted in any setting, for example, hospital 
inpatient, outpatient, primary care or the community, will 
be considered. There will be no language or geographical 
limits. No animal studies will be included.
Exposure
Our exposures are infection with or reactivation of any of 
the eight human herpesvirus infections (defined either 
clinically or through appropriate laboratory criteria), 
herpesvirus vaccinations (eg, Zostavax) and herpesvirus 
treatments (eg, with antiviral agents such as acyclovir).
Comparators
Comparators will vary by study design and will include 
subjects randomised not to receive an antiviral inter-
vention or vaccination (RCTs), people unexposed to 
herpesvirus infections (cohort studies and case–control 
studies) and person time unexposed to herpesviruses 
(self-controlled case series or case crossover studies).
Outcome
The primary outcomes are dementia (all types), diag-
nosed either clinically, with or without neuroimaging 
or by histopathology, and MCI, characterised clinically. 
Where possible, dementia will be further categorised by 
type, for example, AD, vascular dementia, frontotemporal 
dementia and its subcategories, Lewy body dementia, and 
other rare subtypes including Huntington’s disease and 
prion diseases.
Literature searches
We will search the Cochrane Library, Embase, Global 
Health, Medline, PsycINFO, Scopus and Web of Science 
from dates of inception to January 2017. We will also 
search clinical trials registers and grey literature, including 
ClinicalTrials. gov, the New York Academy of Medicine 
Grey Literature Report (www. greylit. org), the Electronic 
Theses Online Service through the British Library 
(http:// ethos. bl. uk) and the ISI Conference Proceed-
ings Citation Index (http:// isknowledge. com). We will 
use medical subject heading (MeSH) terms and keyword 
searches (in the title and abstract) to capture studies of 
infection with, vaccination against or antiviral treatment 
of, any of the eight human herpesviruses (HSV1, HSV2, 
VZV, EBV, cytomegalovirus (CMV), human herpesvirus 
6 (HHV6), HHV7, HHV8) and dementia (including 
subtypes) or MCI. This strategy will be supplemented 
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by reviewing reference lists of eligible articles and rele-
vant reviews. The search strategy has been developed in 
Medline and will be translated for use in other databases 
(see online supplementary appendix 1).
study records
Data management
Search results will be uploaded into an EndNote database 
(V.7.5) and de-duplicated.
Selection process
All titles and abstracts will be scanned for eligibility by 
two researchers in parallel. The full texts of all articles 
that potentially meet the inclusion criteria will then be 
obtained and again reviewed in parallel. We will note 
reasons for rejection of articles at this stage according to a 
hierarchical list (ineligible study design, wrong exposure, 
wrong outcome, insufficient information to calculate 
an effect estimate). Any discrepancies will be discussed 
between reviewers, and consultation with a third reviewer 
will be carried out where necessary.
Data collection process
The data items listed below will be incorporated into a 
pilot data extraction table. Parallel data extraction will 
be carried out for the first three included studies by two 
reviewers and changes to the extraction table made as 
required. Any discrepancies will be discussed and resolved 
through consultation with a third reviewer if necessary. 
Data will be extracted for each remaining study by a single 
reviewer. We will also consider contacting corresponding 
authors of published studies to obtain any further infor-
mation needed using a standardised email template.
Data items
We will design a data extraction table to collect informa-
tion on the following domains:
 ► Population: characteristics of the study population 
(eg, sex and age distribution, ethnicity, immune status, 
APOE4 status), recruitment and sampling methods, 
inclusion/exclusion criteria;
 ► Exposure: exposure status definition and 
identification, number of exposed subjects, any 
exclusions;
 ► Comparators: identification and definition of 
unexposed individuals, number of unexposed 
subjects, any exclusions;
 ► Outcomes: definition and identification of primary 
(dementia or MCI) and secondary outcomes 
(dementia subtypes), number of subjects, any 
exclusions;
 ► Study characteristics: authors, publication year, 
setting/source of participants, design, period of 
study, length of follow-up time (if relevant), aims and 
objectives.
We will record both unadjusted and fully adjusted effect 
estimates for the association between each of the human 
herpesviruses and risk or rate of dementia or MCI. 
Details of the confounders measured and adjusted for 
will be noted. Results of any additional stratified anal-
yses will also be recorded, for example, on virus effects in 
different population subgroups or on dementia subtypes, 
including categories of severity.
outcomes and prioritisation
The primary outcomes are dementia (all types) and MCI. 
Where possible, the neurodegenerative condition leading 
to the syndromes of dementia or MCI will be recorded, for 
example, AD, vascular dementia, mixed AD and vascular 
dementia, frontotemporal dementia and its subcate-
gories, Lewy body dementia, and other rare subtypes 
including Huntington’s disease and prion diseases. A 
priori, we anticipate that most studies will report on AD. 
We have, however, opted for a broader primary outcome 
definition: excluding studies that do not record dementia 
type will limit the statistical power to detect an effect, yet 
identifying a precise dementia aetiology is challenging, 
especially when histopathological diagnosis is not avail-
able. We will prioritise studies in which herpesvirus status 
was ascertained prior to the occurrence of an outcome 
event when assessing study quality. These are likely to be 
longitudinal prospective studies that generate incidence 
rate ratios or HRs, but we will also consider estimates of 
ORs from case–control studies.
risk of bias in individual studies
We will assess the risk of bias in individual studies in line 
with the Cochrane Collaboration approach for both 
randomised and non-randomised studies.17 18 For RCTs 
this will include consideration of the effects of selection 
bias, performance bias, detection bias, attrition bias and 
reporting bias. For observational studies we will consider 
relevant domains, including selection of participants, 
measurement of variables, control for confounding and 
missing data. For each study, each component will be 
assigned a risk of bias category ‘high risk’, ‘low risk’ or 
‘unclear risk’, and a summary risk of bias table produced. 
Two reviewers will assign risk of bias categories in parallel 
for the first three studies and, as before, any discrepan-
cies that cannot be resolved will be discussed with a third 
reviewer. One reviewer will then assign risk of bias catego-
ries for the remaining studies.
data synthesis
We will conduct a narrative synthesis in which evidence 
is grouped by exposure and outcome definitions, and 
we will additionally summarise the results in tables. We 
will assess whether there are sufficient data to investigate 
the effect of herpesviruses on population subgroups or 
subtypes of dementia. We will investigate whether vacci-
nation to prevent herpesvirus infection or reactivation, 
for example, using chickenpox vaccine or herpes zoster 
vaccine mitigates the risk of dementia. We will also 
present any evidence for a modulating effect of antiviral 
treatment against herpesviruses on dementia.
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We will consider performing a meta-analysis if there are 
sufficient numbers of studies with the same design and 
sufficiently homogeneous populations, exposures and 
outcomes to calculate pooled effect estimates. For case–
control studies we will present pooled ORs, for cohort 
studies, pooled rate ratios or HRs, and for case-only 
designs, pooled incidence ratios will be calculated. The 
choice of fixed or random effects models will be guided 
by the level of statistical heterogeneity. We will consider 
the magnitude and direction of effects when interpreting 
I2 values, but will generally take an I2 value of >25% to 
represent moderate or substantial heterogeneity.19 20 
Sources of heterogeneity will be explored by considering 
the use of meta-regression to compare summary estimates 
from different study-level characteristics, such as age of 
the study population, study design and dementia or MCI 
diagnosis. In sensitivity analysis, the most biased studies 
(those with more than one domain classified as high risk 
of bias) will be excluded. If there are sufficient numbers 
of studies, we will investigate the risk of publication bias 
using a funnel plot. All of the statistical analysis will be 
performed using STATA V.14.0.
cumulative evidence
The quality of cumulative evidence across studies for 
an association of each herpesvirus with each outcome 
will then be assessed using selected Grading of Recom-
mendations, Assessment, Development and Evaluations 
criteria that are relevant to the included studies.21 As 
well as risk of bias, these include inconsistency, indirect-
ness, imprecision, publication bias and any additional 
domains deemed appropriate to categorise the strength 
of evidence as ‘high’, ‘moderate’ or ‘low/very low’.
ethics and dissemination
Ethical approval was not required as this study is a system-
atic review of previously published studies. The protocol 
was registered with the International Prospective Register 
of Systematic Reviews (PROSPERO) on 7 January 2017 
(Registration number: CRD42017054684). Any future 
amendments will be documented on the PROSPERO 
website. Results will be submitted for publication in a 
peer-reviewed journal and presented at national and 
international conferences.
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